Intellia Therapeutics, Inc. shares declined over 5% on Monday morning after Morgan Stanley downgraded the stock to ‘Equal ...
Intellia downgraded to market perform at Morgan Stanley on concerns for ATTR-CM candidate nexiguran ziclumeran. Read more ...
Fintel on MSN8h
Morgan Stanley Downgrades Intellia Therapeutics (NTLA)Fintel reports that on January 27, 2025, Morgan Stanley downgraded their outlook for Intellia Therapeutics (NasdaqGM:NTLA) ...
NEW YORK CITY, NY / ACCESS Newswire / January 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...
NEW YORK CITY, NY / ACCESS Newswire / January 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...
The HAELO trial will assess the therapy’s safety and efficacy in 60 adult subjects with Type I or Type II HAE.
Intellia doses the first patient in the phase III HAELO study on NTLA-2002 for treating hereditary angioedema. Stock rises.
NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Intellia ...
The company expects to submit a biologics license application for NTLA-2002 in 2026 and potentially launch it in the US in 2027.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) shares acquire momentum first thing. The Cambridge, Mass.-based Intellia, a leading clinical-stage gene editing company focused on revolutionizing medicine ...
The biotech said it has dosed the first participant in a Phase 3 study of its in vivo gene editing treatment. Elsewhere, the FDA imposed a hold on Atara and lifted another on Amylyx.
An Alphabet-backed startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback